Metabolon Receives NIH Grant to Develop Advanced Monitoring and Predictive Tools for Type 1 Diabetes Progression
Summary
MORRISVILLE, N.C. June 25, 2024 Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, is proud to announce the receipt of a prestigious grant from the National Institutes of Health (NIH) to develop an innovative product aimed at better monitoring and predicting the conversion of preclinical asymptomatic type 1 diabetes (T1D) to clinical symptomatic, insulin-dependent type 1 diabetes.Over 3 million people in the United States live with T1D. Despite advances in medical research, no single FDA-approved test currently can monitor T1D progression beyond simple disease staging. Metabolons new initiative addresses this unmet need by identifying metabolite biomarkers to improve prediction and enable a more detailed understanding of disease progression when evaluated alongside current clinical indicators.Metabolon has a rich history of pioneering advancements in metabolomics. We are dedicated to empowering pharmaceutical and biotechnology companies, as well as academic and government institutions, with comprehensive metabolic insights to drive better health outcomes, said Ro Hastie, CEO of Metabolon. By integrating new metabolite biomarkers with existing clinical indicators, Metabolons efforts will significantly contribute to diabetes research and patient care.